Ramm

RAMM Pharma Completes Acquisition of Canapar Corp.

Retrieved on: 
Tuesday, June 15, 2021
Ramm

Pursuant to the terms of the acquisition, RAMM acquired of all the common shares of Canapar (Canapar Shares) that the Company did not previously own (including Canapar Shares issuable upon the conversion of outstanding promissory notes of Canapar and Canapar Shares issuable upon the exercise of vested stock options of Canapar) in exchange for an aggregate of 21,778,752 common shares of RAMM at a deemed value of $1.20 per RAMM Share (RAMM Shares) for a total purchase price of approximately $26.1 million (the Transaction).

Key Points: 
  • Pursuant to the terms of the acquisition, RAMM acquired of all the common shares of Canapar (Canapar Shares) that the Company did not previously own (including Canapar Shares issuable upon the conversion of outstanding promissory notes of Canapar and Canapar Shares issuable upon the exercise of vested stock options of Canapar) in exchange for an aggregate of 21,778,752 common shares of RAMM at a deemed value of $1.20 per RAMM Share (RAMM Shares) for a total purchase price of approximately $26.1 million (the Transaction).
  • In connection with the completion of the Transaction, RAMM will also issue to RIV approximately 2,105,263 RAMM Shares which RIV was entitled to receive as contingent consideration for sale of the Canapar Shares to RAMM in December 2020.
  • The acquisition of Canapar will be transformational to RAMMs business and our entry into the European market where we see tremendous potential.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Canapar Corp., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Canapar Acquired by RAMM Pharma

Retrieved on: 
Tuesday, May 25, 2021
Devon, Royal Albert Memorial Museum, University of Exeter, Ramm

RAGUSA, Italy, May 25, 2021 (GLOBE NEWSWIRE) -- Canapar Corp. (Canapar) today announced a definitive agreement with RAMM Pharma Corp. (including its wholly owned subsidiaries, RAMM) for RAMM to acquire all the remaining common shares of Canapar.

Key Points: 
  • RAGUSA, Italy, May 25, 2021 (GLOBE NEWSWIRE) -- Canapar Corp. (Canapar) today announced a definitive agreement with RAMM Pharma Corp. (including its wholly owned subsidiaries, RAMM) for RAMM to acquire all the remaining common shares of Canapar.
  • In exchange, Canapar will receive approximately 21 million common shares in RAMM for a total purchase price of approximately CA$26.2 million.
  • Under the agreement, Canapar shareholders will receive approximately 0.54 RAMM shares for each share held in Canapar.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

RAMM Pharma to Acquire 100% of Leading Vertically Integrated European Cannabis Company Canapar Corp.

Retrieved on: 
Wednesday, May 12, 2021
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Ramm, CBD

Additional contracts being actively pursued and negotiated.\nMultiple source business-to-business and business-to-consumer revenue strategy in place to establish Canapar as a leading European supplier of high-margin CBD, active pharmaceutical ingredients (APIs) and wellness products.

Key Points: 
  • Additional contracts being actively pursued and negotiated.\nMultiple source business-to-business and business-to-consumer revenue strategy in place to establish Canapar as a leading European supplier of high-margin CBD, active pharmaceutical ingredients (APIs) and wellness products.
  • The purchase price will be satisfied by the issuance of RAMM Shares to the shareholders of Canapar (other than the Company) having a deemed value equal to C$1.20 per RAMM Share.
  • Mr. Martines will also be appointed to the senior management team of the Company and will keep the position of Chief Executive Officer of Canapar Corp.
  • Mr. Varela is ideally suited to lead the Company\xe2\x80\x99s financial oversight with his unique experience in the European and South American cannabis industry.

Early Warning Reports Issued Pursuant to National Instrument 62-103 in Connection with the Completion of Private Share Sales

Retrieved on: 
Thursday, April 29, 2021
Stock market, Equity securities, Corporate finance, Devon, Ramm, Share, Stock, Security, Royal Albert Memorial Museum, Economy, Academic disciplines

b'TORONTO, April 29, 2021 (GLOBE NEWSWIRE) -- Jack Burnett, President and a director of Ramm Pharma Corp. ("Ramm" or, the "Company"), Daniel Augereau, a director of the Company, and Armando Blankleider, a former reporting insider of the Company, each announced that they have filed an early warning report (collectively, the "Early Warning Reports") under National Instrument 62-103 \xe2\x80\x93 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the completion of certain private sales of common shares of Ramm (the "Ramm Shares").\nMr.

Key Points: 
  • b'TORONTO, April 29, 2021 (GLOBE NEWSWIRE) -- Jack Burnett, President and a director of Ramm Pharma Corp. ("Ramm" or, the "Company"), Daniel Augereau, a director of the Company, and Armando Blankleider, a former reporting insider of the Company, each announced that they have filed an early warning report (collectively, the "Early Warning Reports") under National Instrument 62-103 \xe2\x80\x93 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the completion of certain private sales of common shares of Ramm (the "Ramm Shares").\nMr.
  • Blankleider sold an aggregate of 10,000,000 Ramm Shares at a price of $0.23 per Ramm Share pursuant to private share sale agreements (the "Share Sale Agreements") for aggregate proceeds to Mr. Blankleider of $2,300,000.
  • Mr. Burnett acquired 2,000,000 Ramm Shares and Mr. Augereau acquired 4,000,000 Ramm Shares from Mr. Blankleider in connection with the share sale transactions.\nImmediately prior to the disposition of the Ramm Shares by Mr. Blankleider, Mr. Blankleider beneficially owned or controlled 19,671,500 Ramm Shares, representing approximately 19.7% of the issued and outstanding Ramm Shares on a non-diluted basis.
  • Following the completion of the transactions pursuant to the Share Sale Agreements, Mr. Blankleider beneficially owned or controlled an aggregate of 9,671,500 Ramm Shares representing approximately 9.7% of the issued and outstanding Ramm Shares on a non-diluted basis.\nImmediately prior to the acquisition of the Ramm Shares, Mr. Burnett beneficially owned or controlled 17,700,000 Ramm Shares and 3,000,000 incentive stock options, representing approximately 17.8% of the issued and outstanding Ramm Shares on a non-diluted basis, and approximately 20.2% of the Ramm Shares on a partially-diluted basis, assuming the exercise of all convertible securities of the Company held by Mr. Burnett.

RAMM Pharma Initiates Clinical Trials of its Proprietary NettaVet™ Cannabinoid Formulation for Multiple Pathologies in Animals

Retrieved on: 
Thursday, March 25, 2021
Ramm, Pharma

TORONTO, March 25, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the Company or "RAMM") (CSE: RAMM) (OTC: RAMMF), a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that it has initiated clinical trials studying the efficacy of its proprietary NettaVet pet cannabinoid formulation for the treatment of four pathologies in animals.

Key Points: 
  • TORONTO, March 25, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the Company or "RAMM") (CSE: RAMM) (OTC: RAMMF), a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that it has initiated clinical trials studying the efficacy of its proprietary NettaVet pet cannabinoid formulation for the treatment of four pathologies in animals.
  • NettaLife is a wholly owned subsidiary of RAMM, dedicated to the production, export and commercialization of pet products, food, pharmaceutical specialties and cosmetic products for animals.
  • The clinical trials are designed to address some of the most common ailments in dogs and horses.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and Ramm Pharma Holdings Corp.

RAMM Pharma Selected as COVID-19 Vaccine Fulfilment & Distribution Partner by the Uruguayan Ministry of Health

Retrieved on: 
Tuesday, February 23, 2021
Ramm, Pharma

TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the Company or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that the Uruguayan Ministry of Public Health, (Ministerio de Sald Publica or MSP) has selected RAMM as a fulfilment and distribution partner for Uruguays COVID-19 vaccination program.

Key Points: 
  • TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the Company or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that the Uruguayan Ministry of Public Health, (Ministerio de Sald Publica or MSP) has selected RAMM as a fulfilment and distribution partner for Uruguays COVID-19 vaccination program.
  • Under the arrangement, RAMM will be responsible for the sterilization, packaging and distribution of syringes and other medical supplies for use in the countrys COVID-19 vaccination program.
  • RAMMs state-of-the-art GMP certified pharmaceutical facility was selected for the program upon satisfaction of the stringent requirements of the Ministry of Public Health.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and Ramm Pharma Holdings Corp.

Canapar Welcomes RAMM Pharma as Strategic Shareholder; Closes $6,427,000 Financing

Retrieved on: 
Wednesday, January 20, 2021
Drugs, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Devon, Royal Albert Memorial Museum, Ramm, Hemp, CBD, Organ systems

RAGUSA, Italy, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Canapar Corp. (Canapar) and RAMM Pharma Corp. (including its wholly owned subsidiaries, "RAMM") (CSE: RAMM) are pleased to announce they have entered into a strategic partnership, combining Canapars hemp-derived cannabidiol (CBD) extraction expertise with RAMMs leadership in cannabis-derived pharmaceutical and cosmeceutical products.

Key Points: 
  • RAGUSA, Italy, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Canapar Corp. (Canapar) and RAMM Pharma Corp. (including its wholly owned subsidiaries, "RAMM") (CSE: RAMM) are pleased to announce they have entered into a strategic partnership, combining Canapars hemp-derived cannabidiol (CBD) extraction expertise with RAMMs leadership in cannabis-derived pharmaceutical and cosmeceutical products.
  • As part of the strategic partnership, RAMM has acquired Canopy Rivers (TSX: RIV) (OTC: CNPOF) 49% ownership interest in Canapar.
  • This investment is expected to immediately enhance both RAMM and Canapars ability to capitalize on the rapidly expanding European and South American hemp-derived CBD markets.
  • "We are very excited to welcome RAMM as our newest partner, said Sergio Martines, CEO, Canapar.

RAMM Pharma Makes Additional Investment in Canapar & Provides Overview of Strategic Acquisition to Enter European Cannabis Market

Retrieved on: 
Tuesday, January 5, 2021
Ramm, Devon, Royal Albert Memorial Museum, Counties of England

Further to its news release dated December 30, 2020 announcing its acquisition of 29,833,333 shares of Canapar, representing an approximate 49% interest, this subscription further strengthens Ramms strategic relationship with Canapar.

Key Points: 
  • Further to its news release dated December 30, 2020 announcing its acquisition of 29,833,333 shares of Canapar, representing an approximate 49% interest, this subscription further strengthens Ramms strategic relationship with Canapar.
  • Based in Italy, Canapar is positioned to become one of Europes largest vertically integrated Cannabis companies.
  • This investment will accelerate Canapars ability to establish itself as a leader in the European market and the realization of the strategic benefits to RAMM, stated Jack Burnett, Chief Executive Officer of RAMM.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and Ramm Pharma Holdings Corp, and a 49% equity interest in Canapar.

RAMM Pharma Enters European Cannabis Market with Strategic Investment in Canapar Corp.

Retrieved on: 
Wednesday, December 30, 2020
Devon, Royal Albert Memorial Museum, Ramm, Counties of England

The Canapar Shares were acquired from Canopy Rivers Corporation (Canopy Rivers), a wholly owned subsidiary of Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF).

Key Points: 
  • The Canapar Shares were acquired from Canopy Rivers Corporation (Canopy Rivers), a wholly owned subsidiary of Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF).
  • Canapar, through its wholly owned subsidiary Canapar SrL (Canapar Italy), will be one of Europes largest vertically integrated Cannabis companies when fully operational.
  • Canapar is positioned to be a leader in the European Cannabis market and this strategic investment provides RAMM with a significant presence in Europe creating a prominent and differentiated global platform, stated Jack Burnett, Chief Executive Officer of RAMM.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and Ramm Pharma Holdings Corp.

Canopy Rivers Sells Interest in Italy-Based Canapar

Retrieved on: 
Wednesday, December 30, 2020
Ramm, Devon, Royal Albert Memorial Museum, Counties of England

TORONTO, Dec. 30, 2020 /PRNewswire/ -Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSX: RIV) (OTC: CNPOF), through its wholly-owned subsidiary, Canopy Rivers Corporation, has entered into a definitive share purchase agreement (the "Share Purchase Agreement"), effective as of December 30, 2020, with RAMM Pharma Corp. ("RAMM") (CSE: RAMM), pursuant to which the Company has sold its 49% common equity interest in Canapar Corp. ("Canapar") to RAMM for consideration of up to $9.0 million (the "Transaction").

Key Points: 
  • TORONTO, Dec. 30, 2020 /PRNewswire/ -Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSX: RIV) (OTC: CNPOF), through its wholly-owned subsidiary, Canopy Rivers Corporation, has entered into a definitive share purchase agreement (the "Share Purchase Agreement"), effective as of December 30, 2020, with RAMM Pharma Corp. ("RAMM") (CSE: RAMM), pursuant to which the Company has sold its 49% common equity interest in Canapar Corp. ("Canapar") to RAMM for consideration of up to $9.0 million (the "Transaction").
  • Under the terms of the Share Purchase Agreement, on closing, RAMM delivered a cash payment of $7.0 million to Canopy Rivers to purchase the Company's 29,833,333 common shares in Canapar.
  • "The divestment of our equity interest in Canapar represents an important reallocation of capital as we adjust our go-forward investment strategy," said Narb Alexandrian, President and CEO, Canopy Rivers.
  • Canopy Rivers initially invested in Sicily-based Canapar in the summer of 2018, and subsequently led a $25 million financingin early 2019.